Biotechnology

Aptevo Therap

Aptevo Therapeutics Showcases APVO451 Preclinical Data

Aptevo Therap released FY2025 9 Months earnings on November 6 (EST), actual revenue USD 0, actual EPS USD -98.5079

Aptevo Therap released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.2296 (forecast USD -2.09)

Aptevo Therap released FY2025 Q2 earnings on August 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -8.4048 (forecast USD -83.2)

Aptevo Therap released FY2025 Semi-Annual earnings on August 11 (EST), actual revenue USD 0, actual EPS USD -30.8373

Aptevo Therapeutics Files Dirk Huebner as Beneficial Owner

Aptevo Therapeutics Switches to New Independent Auditor

Aptevo Therapeutics Inc. Plans to Issue Common Stock

Aptevo Therapeutics Inc. Completes $8 Million Financing

Aptevo Therapeutics Introduces New Candidate Drug APVO455 for Solid Tumors

Aptevo Therapeutics Inc. Issues $8 Million in Stock

Aptevo Therapeutics' AML Bispecific Antibody Trial Yields Positive Results

Aptevo Therapeutics Signs Equity Purchase Agreement with Yorkville

Aptevo Therapeutics Inc. Attends BIO International Convention

Aptevo Therapeutics Announces 1 for 20 Reverse Stock Split

Aptevo Therapeutics Inc. reports Q1 EPS loss of $4.39

Aptevo Therap released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -87.8735 (forecast USD -84.2)

Aptevo Reports Q1 Earnings and Mipletamig Clinical Progress

Aptevo Therapeutics Updates Progress on APVO711 Antibody

Aptevo Therapeutics Inc forecasts Q4 EPS loss of 4.21 USD

Treasure Gbl

SMX Security Matters

Wheeler Real Estate

Gulf Resources

DigitalBridge

Toro

Dreamland

Lichen

Springview

Alumis

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap